Magazine Article | January 2, 2019

From Lab To Lawsuit: Litigation Risks In Pharma-Licensing Agreements

Source: Life Science Leader

By Michael German, Mark Goodman and Henry Lebowitz

In recent years, larger pharmaceutical companies have expanded their developmental pipelines by entering into collaborative agreements with smaller drug-development companies to in-license potential new products.

When successful, such agreements allow the licensee to expand its drug portfolio and the licensor to take advantage of the licensee’s expertise. When such agreements fail, however, the result is often that one or both sides suffer significant economic and reputational harm. Lawsuits invariably follow soon thereafter. Litigating these types of cases is costly, and the loser is often faced with a large monetary penalty. While licensees in these types of collaboration agreements often have the resources to manage such litigation, licensors do not.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: